- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01940679
Bioavailability of Encapsulated Omega-3 Fatty Acids
March 3, 2014 updated by: Tracey Smith, United States Army Research Institute of Environmental Medicine
Omega-3 fatty acids (n-3s), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have anti-inflammatory properties and other documented beneficial health effects that could warrant n-3 fortification of combat rations.
However, military combat rations must meet rigorous shelf-stability guidelines (e.g.,, 3 years at 80°F or 6 months at 100°F), which is problematic for natural food sources of n-3s (e.g., oil and fish), which degrade when exposed to high temperatures and prolonged shelf-storage.
Encapsulation, e.g., coating freeze dried n-3s with gelatin, can prevent this degradation, and Natick Soldier Research, Development and Engineering Center's (NSRDEC) Combat Feeding Directorate used encapsulated n-3 technology to produce n-3 enriched ration items that withstand environmental stressors and meet shelf-life specifications for military rations.
However, the bioavailability of the encapsulated n-3s in these rations is unknown, particularly when they are incorporated into high-protein food items and exposed to high temperatures and prolonged storage.
In this randomized, cross-over study, civilian and/or military personnel will be asked to consume: 1) a high protein food item enriched with encapsulated n-3s (600 mg) and previously stored for 6 months at 100°F; 2) a low-protein food item enriched with encapsulated n-3s (600 mg) and previously stored for 6 months at 100°F; 3) a high protein food item with encapsulated n-3s (600 mg) that was not subjected to high-temperature and prolonged storage; and, 4) a low-protein food item with encapsulated n-3s (600 mg) that was not subjected to high temperature and prolonged storage.
Serial blood sampling to measure acute changes in the circulating fatty acid profile will occur in the hour before and 6 hours after consumption of each ration component.
The only known risks, which this study presents to participants, are those associated with venous catheter placement.
The results will help military ration developers determine the ration components best suited for n-3 fortification.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
14
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Natick, Massachusetts, United States, 01760
- U.S. Army Research Institute of Environmental Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- between 18 and 45 years old
- leave status and have approval from your supervisor (for DoD Civilians)
Exclusion Criteria:
- under the age of 18 or over the age of 45
- bleeding disorder (von Willebrand disease, hemophilia) or taking medications that impair ability to stop bleeding (heparin)
- consumed ≥1 serving (equivalent to a deck of cards) of salmon, herring, mackerel, anchovies, sardines, halibut or tuna or omega-3 enriched eggs per week over the previous past month
- regularly consume dietary supplements (for example, capsules) containing omega-3 fatty acids
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Fresh meat stick
Fresh meat stick w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.
|
encapsulated 600 mg EPA/DHA
|
|
Experimental: Stored meat stick
Stored meat stick with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production
|
encapsulated 600 mg EPA/DHA
|
|
Experimental: Fresh pound cake
Fresh pound cake w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.
|
encapsulated 600 mg EPA/DHA
|
|
Experimental: Stored pound cake
Stored pound cake with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production.
|
encapsulated 600 mg EPA/DHA
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Plasma n-3 concentrations
Time Frame: 15 minute, 2 hrs, 4 hrs and 6 hrs after consumption of n-3 rich food item
|
15 minute, 2 hrs, 4 hrs and 6 hrs after consumption of n-3 rich food item
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Tracey J Smith, PhD, U.S. Army Research Institute of Environmental Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2013
Primary Completion (Actual)
December 1, 2013
Study Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
September 9, 2013
First Submitted That Met QC Criteria
September 9, 2013
First Posted (Estimate)
September 12, 2013
Study Record Updates
Last Update Posted (Estimate)
March 4, 2014
Last Update Submitted That Met QC Criteria
March 3, 2014
Last Verified
March 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- 13-13-H
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bioavailability of Omega-3s in Military Rations
-
University of LimerickMarigot Ltd.; Enterprise IrelandCompletedBioavailability of Amino Acids Following Oral Ingestion of Plant-Based Proteins in Young, Healthy MenIreland
-
University Hospitals, LeicesterCompletedAssess Effect of Omega-3 Fish Oil in Patients With Severe Acute PancreatitisUnited Kingdom
-
Allama Iqbal Open University IslamabadKing Edward Medical UniversityCompletedRole of Omega-3 Polyunsaturated Fatty Acid in the Management of Major Depressive Disorder: A Randomized Controlled TrialPakistan
Clinical Trials on encapsulated 600 mg EPA/DHA
-
Colorado State UniversityUSDA Beltsville Human Nutrition Research CenterCompleted
-
SCF PharmaCompleted
-
National Science Council, TaiwanCompletedMajor Depressive DisorderTaiwan
-
Midwest Center for Metabolic and Cardiovascular...NaturmegaCompleted
-
The Jerzy Kukuczka Academy of Physical Education...Enrolling by invitationHealthy VolunteersPoland
-
Cardiovascular Research AssociatesDupont Applied BiosciencesCompletedHeart DiseaseUnited States
-
Laval UniversityCanadian Institutes of Health Research (CIHR)CompletedCardiovascular Disease, InflammationCanada
-
Vanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI); GlaxoSmithKline; eCardio DiagnosticsCompletedAtrial FibrillationUnited States
-
Johns Hopkins UniversityTerminated
-
Rabin Medical CenterUnknown